From: Model system for the analysis of cell surface expression of human ABCA1
Drug | Known effect | ABCA1 cell surface expression | |
---|---|---|---|
HA-WT | HA-MM | ||
ALLN | Calpain inhibitor | ⇧ (+ 60%) | ⇧ (+ 30%) |
ApoA-I | cholesterol acceptor | ⇧ (+ 30%) | no effect |
Atorvastatin | cholesterol level lowering | no effect | no effect |
Brefeldin A | trans-Golgi transport inhibitor | ⇩ (- 60%) | ⇩ (- 40%) |
Cycloheximide | protein synthesis inhibitor | ⇩ (- 30%) (viability ⇩) | ⇩(- 30%) (viability ⇩) |
Cyclosporin A | immunosuppressor | ⇧ (+ 60%) | ⇧ (+ 60%) |
Ezetimibe | inhibitor of intestinal cholesterol absorption | ⇩ (- 20%) | no effect |
Glyburide | ABCA1 inhibitor | no effect | no effect |
Niacin | cholesterol level lowering | no effect | no effect |
Nifedipine | Ca2+-channel blocker | no effect | no effect |
Methyl-β-cyclodextrin | cholesterol depletion | no effect (viability ⇩) | no effect (viability ⇩) |
Cholesterol-methyl-β-cyclodextrin | cholesterol overloading | no effect (viability ⇧) | no effect (viability ⇧) |
Verapamil | Ca2+-channel blocker | no effect | no effect |